Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Preliminary results of a phase I/II study involving natural killer chimeric antigen receptor (CAR-NK) therapy for treatment of relapsed non-Hodgkin lymphomas and chronic lymphocytic leukemia.